An Open-label Study of CND261 in Seropositive Rheumatoid Arthritis

Exclusion Criteria

• •1. Inadequate clinical laboratory parameters at Screening
• •2. Active infection
• •3. Receipt of or inability to discontinue any excluded therapies
• •4. Receipt of live vaccine within 4 weeks
• •5. Presence of any concomitant autoimmune disease
• •6. Active or known history of catastrophic anti-phospholipid syndrome
• •7. APS or thrombotic event not adequately controlled by anticoagulation therapy
• •8. History of progressive multifocal leukoencephalopathy
• •9. Central nervous system disease
• •10. Presence of 1 or more significant concurrent medical conditions
• •11. Have a diagnosis or history of malignant disease within 5 years
• •12. Serious mental illness, alcohol or drug abuse, dementia, or any other condition that would impair ability to receive planned treatment or to understand informed consent
• •13. History of or planned organ transplant and/or autologous or allogeneic hematopoietic stem cell transplantation
• •14. Major surgery requiring use of general anesthesia within 12 weeks or planned or expected major surgery during the study
• •15. Women who are pregnant or breastfeeding
• •16. Patients who do not agree to the use of highly effective contraception as defined by the protocol